MALDI-TOF Serum Protein Profiling for the Detection of Breast Cancer

Proteomic expression profiling has been suggested as a potential tool for the early diagnosis of cancer and other diseases. The objective of our study was to assess the feasibility of this approach for the detection of breast cancer. Materials and Methods: In a randomized block design pre-operative serum samples obtained from 78 breast cancer patients and 29 controls were used to generate high-resolution MALDI-TOF protein profiles. The spectra generated using C8 magnetic beads assisted mass spectrometry were smoothed, binned and normalized after baseline correction. Linear discriminant analysis with double cross-validation, based on principal component analysis, was used to classify the protein profiles. Results: A total recognition rate of 99%, a sensitivity of 100%, and a specificity of 97.0% for the detection of breast cancer were shown. The area under the curve of the classifier was 98.3%, which demonstrates the separation power of the classifier. The first 2 principal components account for most of the between- group separation. Conclusions: Double cross-validation showed that classification could be attributed to actual information in the protein profiles rather than to chance. Although preliminary, the high sensitivity and specificity indicate the potential usefulness of serum protein profiles for the detection of breast cancer.

[1]  S. Addelman.  Statistics for experimenters , 1978 .

[2]  Yoshua Bengio,et al.  Pattern Recognition and Neural Networks , 1995 .

[3]  Wojtek J. Krzanowski,et al.  Selection of variables, and assessment of their performance, in mixed-variable discriminant analysis , 1995 .

[4]  J F Simpson,et al.  Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: results from the Eastern Cooperative Oncology Group Companion Study, EST 4189. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Dechang Chen,et al.  The Theory of the Design of Experiments , 2001, Technometrics.

[6]  E. Petricoin,et al.  Serum proteomic patterns for detection of prostate cancer. , 2002, Journal of the National Cancer Institute.

[7]  P. Schellhammer,et al.  Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. , 2002, Cancer research.

[8]  I. Jolliffe.  Principal Component Analysis , 2002 .

[9]  Russell V. Lenth,et al.  The Theory of the Design of Experiments , 2002 .

[10]  E. Fung,et al.  Proteomic approaches to tumor marker discovery. , 2002, Archives of pathology & laboratory medicine.

[11]  Bart J A Mertens,et al.  Microarrays, pattern recognition and exploratory data analysis , 2003, Statistics in medicine.

[12]  Richard Baumgartner,et al.  Class prediction and discovery using gene microarray and proteomics mass spectroscopy data: curses, caveats, cautions , 2003, Bioinform..

[13]  Min Zhan,et al.  A data review and re-assessment of ovarian cancer serum proteomic profiling , 2003, BMC Bioinformatics.

[14]  Mark S. Boguski,et al.  Biomedical informatics for proteomics , 2003, Nature.

[15]  Bill C. White,et al.  Proteomic patterns of tumour subsets in non-small-cell lung cancer , 2003, The Lancet.

[16]  Jeffrey S. Morris,et al.  Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments , 2004, Bioinform..

[17]  D. Ransohoff.  Rules of evidence for cancer molecular-marker discovery and validation , 2004, Nature Reviews Cancer.

[18]  S. Astley.  Computer-based detection and prompting of mammographic abnormalities. , 2004, The British journal of radiology.

[19]  E. Diamandis.  Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. , 2004, Journal of the National Cancer Institute.

[20]  E. Holland,et al.  Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. , 2004, Analytical chemistry.

[21]  Jeffrey S. Morris,et al.  The importance of experimental design in proteomic mass spectrometry experiments: some cautionary tales. , 2005, Briefings in functional genomics & proteomics.

[22]  K. Coombes,et al.  Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery. , 2005, Journal of proteome research.

[23]  E. Diamandis,et al.  Plasma protein profiling by mass spectrometry for cancer diagnosis: opportunities and limitations. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  S. Baumann,et al.  Standardized approach to proteome profiling of human serum based on magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. , 2005, Clinical chemistry.

[25]  Jeffrey S. Morris,et al.  Serum proteomics profiling—a young technology begins to mature , 2005, Nature Biotechnology.

[26]  André M Deelder,et al.  Reliability of human serum protein profiles generated with C8 magnetic beads assisted MALDI-TOF mass spectrometry. , 2005, Analytical chemistry.

[27]  E. Espinosa,et al.  High-throughput techniques in breast cancer: a clinical perspective. , 2006, European journal of cancer.

[28]  A. Olshen,et al.  Differential exoprotease activities confer tumor-specific serum peptidome patterns. , 2005, The Journal of clinical investigation.

[29]  H. Iwase,et al.  [Breast cancer]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.

[30]  E. Petricoin,et al.  Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. , 2005, The Journal of clinical investigation.

[31]  Cornelis J H van de Velde,et al.  Detection of colorectal cancer using MALDI-TOF serum protein profiling. , 2006, European journal of cancer.